Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Clinical trial NCT03692767 · UNKNOWN
Trial details
- NCT number
- NCT03692767
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-01
- Primary completion
- 2020-11-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.